CT-1498: A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)Krish Patel, Matthew Ku, Nosha Farhadfar et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
ORAL ABSTRACT: CT-1498 A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (Car) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)Krish Patel, Matthew Ku, Joanna Rhodes et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
POSTER: CT-1498 A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)Krish Patel, Matthew Ku, Joanna Rhodes et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0